Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial.

Autor:	Tang A; Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada an.tang@umontreal.ca., Rabasa-Lhoret R; Institut de Recherches Cliniques de Montréal, Montréal, Québec, Canada Department of Medicine and Endocrinology, Centre Hospitalier de l'Université de Montréal (CHUM), Hôpital Hotel-Dieu, Montréal, Québec, Canada., Castel H; Department of Gastroenterology and Hepatology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada., Wartelle-Bladou C; Department of Gastroenterology and Hepatology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada., Gilbert G; Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Hôpital Notre-Dame, Montréal, Québec, Canada MR Clinical Science, Philips Healthcare Canada, Markham, Ontario, Canada., Massicotte-Tisluck K; Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada., Chartrand G; Imaging and Orthopaedics Research Laboratory (LIO), École de Technologie Supérieure, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada., Olivié D; Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada., Julien AS; Department of Mathematics and Statistics, Pavillon André-Aisenstadt, Université de Montréal, Montréal, Québec, Canada., de Guise J; Imaging and Orthopaedics Research Laboratory (LIO), École de Technologie Supérieure, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada., Soulez G; Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada., Chiasson JL; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada Department of Medicine and Endocrinology, Centre Hospitalier de l'Université de Montréal (CHUM), Hôpital Hotel-Dieu, Montréal, Québec, Canada.
Jazyk:	angličtina
Zdroj:	Diabetes care [Diabetes Care] 2015 Jul; Vol. 38 (7), pp. 1339-46. Date of Electronic Publication: 2015 Mar 26.
DOI:	10.2337/dc14-2548
Abstrakt:	Objective: This study determined the effects of insulin versus liraglutide therapy on liver fat in patients with type 2 diabetes inadequately controlled with oral agents therapy, including metformin. Research Design and Methods: Thirty-five patients with type 2 diabetes inadequately controlled on metformin monotherapy or in combination with other oral antidiabetic medications were randomized to receive insulin glargine or liraglutide therapy for 12 weeks. The liver proton density fat fraction (PDFF) was measured by MRS. The mean liver PDFF, the total liver volume, and the total liver fat index were measured by MRI. The Student t test, the Fisher exact test, and repeated-measures ANOVA were used for statistical analysis. Results: Insulin treatment was associated with a significant improvement in glycated hemoglobin (7.9% to 7.2% [62.5 to 55.2 mmol/mol], P = 0.005), a trend toward a decrease in MRS-PDFF (12.6% to 9.9%, P = 0.06), and a significant decrease in liver mean MRI-PDFF (13.8% to 10.6%, P = 0.005), liver volume (2,010.6 to 1,858.7 mL, P = 0.01), and the total liver fat index (304.4 vs. 209.3 % ⋅ mL, P = 0.01). Liraglutide treatment was also associated with a significant improvement in glycated hemoglobin (7.6% to 6.7% [59.8 to 50.2 mmol/mol], P < 0.001) but did not change MRS-PDFF (P = 0.80), liver mean MRI-PDFF (P = 0.15), liver volume (P = 0.30), or the total liver fat index (P = 0.39). Conclusions: The administration of insulin glargine therapy reduced the liver fat burden in patients with type 2 diabetes. However, the improvements in the liver fat fraction and glycemia control were not significantly different from those in the liraglutide group. (© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu